Paper Details

  1. Home
  2. Paper Details

Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT.

Author: AyariS, ChevallierP, DelaunayJ, GastinneT, GuillaumeT, Le GouillS, LoiratM, MohtyM, MoreauP, PeterlinP, TessoulinB

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study retrospectively analyzed the outcomes of 31 patients with hematopoietic malignancies who received azacitidine for post-transplant relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). While some patients achieved durable remissions, the toxicity related to azacitidine was high, suggesting that early administration after transplant followed by donor lymphocyte infusion should be considered as a pre-emptive therapy for potential relapse.
Paper Details　
Original Abstract of the Article :
Patients with hematopoietic malignancies relapsing after allogeneic hematopoietic SCT (allo-HSCT) have a poor prognosis. We retrospectively analyzed the patients who received azacitidine in our center in the course of treatment of their post-transplant relapse. We identified 31 patients. Relapse occ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/bmt.2013.233

データ提供：米国国立医学図書館（NLM）

Azacitidine: A Salvage Therapy for Relapsed Myeloid Malignancies

This research delves into the complex world of hematologic malignancies, exploring the potential of azacitidine, a chemotherapy drug, in treating patients with myeloid malignancies who have relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study retrospectively analyzed data from 31 patients who received azacitidine as a salvage therapy, investigating its efficacy and safety in this challenging setting.

Azacitidine: A Potential Salvage Therapy for Relapsed Myeloid Malignancies

The study found that azacitidine induced durable remissions in a small proportion of patients with relapsed myeloid malignancies after allo-HSCT. However, the overall response rate was modest, and the toxicity associated with azacitidine was significant. The study highlights the need for further investigation into the optimal use of azacitidine in this patient population.

Navigating the Challenges of Relapsed Myeloid Malignancies

This research provides valuable insights into the challenges of treating relapsed myeloid malignancies after allo-HSCT. While azacitidine may offer a potential salvage therapy for a select group of patients, its use should be carefully considered due to its associated toxicity. This study emphasizes the need for ongoing research to develop more effective and less toxic treatment options for patients with relapsed myeloid malignancies. It is crucial to remember that cancer treatment is a complex and personalized process that requires a comprehensive evaluation of individual patient needs and risk factors.

Dr. Camel's Conclusion

This study explores the use of azacitidine as a salvage therapy for patients with relapsed myeloid malignancies after allo-HSCT. While azacitidine induced durable remissions in a small proportion of patients, its use should be carefully considered due to its associated toxicity. This study underscores the need for ongoing research to develop more effective and less toxic treatment options for patients with relapsed myeloid malignancies.

Date :
  1. Date Completed 2015-01-14
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24488048

DOI: Digital Object Identifier

10.1038/bmt.2013.233

Related Literature

Article Analysis
・Side Effects of azacitidine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.